Home » Stocks » BLPH

Bellerophon Therapeutics, Inc. (BLPH)

Stock Price: $6.34 USD -0.07 (-1.09%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $6.69 +0.35 (5.52%) Mar 5, 5:48 PM
Market Cap 60.22M
Revenue (ttm) n/a
Net Income (ttm) -20.80M
Shares Out 9.49M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $6.34
Previous Close $6.41
Change ($) -0.07
Change (%) -1.09%
Day's Open 6.41
Day's Range 5.85 - 6.41
Day's Volume 81,215
52-Week Range 3.19 - 26.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

GlobeNewsWire - 3 months ago

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

GlobeNewsWire - 3 months ago

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

GlobeNewsWire - 3 months ago

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

Zacks Investment Research - 4 months ago

Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahea...

GlobeNewsWire - 4 months ago

WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

GlobeNewsWire - 4 months ago

WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t...

GlobeNewsWire - 5 months ago

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developin...

GlobeNewsWire - 6 months ago

WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...

GlobeNewsWire - 7 months ago

WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...

GlobeNewsWire - 7 months ago

Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo

GlobeNewsWire - 7 months ago

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States Initiation of the COViNOX ...

GlobeNewsWire - 8 months ago

WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary a...

GlobeNewsWire - 9 months ago

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public o...

GlobeNewsWire - 9 months ago

WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,0...

GlobeNewsWire - 9 months ago

WARREN, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its ...

GlobeNewsWire - 9 months ago

WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing ...

GlobeNewsWire - 10 months ago

IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program IND Submission Follows Completed Treatment of Sever...

Seeking Alpha - 11 months ago

Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic

GlobeNewsWire - 11 months ago

WARREN, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previous...

GlobeNewsWire - 11 months ago

WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced tha...

GuruFocus - 11 months ago

The Food and Drug Administration has thrown a lifeline to a little known and beleaguered New Jersey therapeutics company, thrusting it into the search for Covid-19 treatments.

Benzinga - 11 months ago

Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) gap-opened higher Friday morning and were holding on to the gains during the trading session.

GlobeNewsWire - 11 months ago

WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced tha...

GlobeNewsWire - 11 months ago

WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the...

Benzinga - 1 year ago

Shares of biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) were  more than doubling Tuesday following a positive clinical readout from the company.

GlobeNewsWire - 1 year ago

WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced posi...

GlobeNewsWire - 1 year ago

WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the ...

Market Watch - 1 year ago

Shares of Bellerophon Therapeutics Inc. BLPH, +2.03% gained 38% in premarket trading on Tuesday after its experimental therapy to treat certain forms of pulmonary hypertension reported positiv...

GlobeNewsWire - 1 year ago

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity

GlobeNewsWire - 1 year ago

WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced posi...

GlobeNewsWire - 1 year ago

Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefit...

GuruFocus - 1 year ago

According to these filters, the following are significant trades from company insiders this month.

Other stocks mentioned: BRP, CMCSA, OPK, PGNY, STON
GlobeNewsWire - 1 year ago

Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition

GlobeNewsWire - 1 year ago

Results to be Presented in Late-Breaking Abstract as an Oral Presentation

GlobeNewsWire - 1 year ago

WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the...

GlobeNewsWire - 1 year ago

WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today tha...

About BLPH

Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension assoc... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2015
CEO
Fabian Tenenbaum
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
BLPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BLPH stock is "Buy." The 12-month stock price forecast is 23.67, which is an increase of 273.34% from the latest price.

Price Target
$23.67
(273.34% upside)
Analyst Consensus: Buy